Detailed information for compound 522581

Basic information

Technical information
  • TDR Targets ID: 522581
  • Name: 5-[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyet hyl]amino]ethyl]phenyl]thiophene-2-carboxylic acid
  • MW: 401.906 | Formula: C21H20ClNO3S
  • H donors: 3 H acceptors: 3 LogP: 2.15 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: Clc1cccc(c1)[C@H](CNCCc1ccc(cc1)c1ccc(s1)C(=O)O)O
  • InChi: 1S/C21H20ClNO3S/c22-17-3-1-2-16(12-17)18(24)13-23-11-10-14-4-6-15(7-5-14)19-8-9-20(27-19)21(25)26/h1-9,12,18,23-24H,10-11,13H2,(H,25,26)/t18-/m0/s1
  • InChiKey: CHSPXANSXHDQCC-SFHVURJKSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 5-[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxy-ethyl]amino]ethyl]phenyl]thiophene-2-carboxylic acid
  • 5-[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-2-thiophenecarboxylic acid
  • 5-[4-[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxy-ethyl]amino]ethyl]phenyl]-2-thenoic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens adrenoceptor beta 3 Starlite/ChEMBL References
Homo sapiens adrenoceptor beta 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni glycogen phosphorylase 0.0218 0.5 0.5
Entamoeba histolytica glycogen phosphorylase, putative 0.0218 0.5 0.5
Echinococcus multilocularis glycogen phosphorylase 0.0218 0.5 0.5
Trichomonas vaginalis glycogen phosphorylase, putative 0.0218 0.5 0.5
Schistosoma mansoni glycogen phosphorylase 0.0218 0.5 0.5
Echinococcus granulosus Glycosyl transferase family 35 0.0218 0.5 0.5
Onchocerca volvulus Glycogen phosphorylase homolog 0.0218 0.5 0.5
Loa Loa (eye worm) glycogen phosphorylase 0.0218 0.5 0.5
Giardia lamblia Glycogen phosphorylase 0.0218 0.5 0.5
Trichomonas vaginalis glycogen phosphorylase, putative 0.0218 0.5 0.5
Echinococcus granulosus glycogen phosphorylase 0.0218 0.5 0.5
Echinococcus multilocularis Glycosyl transferase, family 35 0.0218 0.5 0.5
Echinococcus multilocularis glycogen phosphorylase 0.0218 0.5 0.5
Entamoeba histolytica glycogen phosphorylase, putative 0.0218 0.5 0.5
Chlamydia trachomatis glycogen phosphorylase 0.0218 0.5 0.5
Echinococcus granulosus glycogen phosphorylase 0.0218 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
EC50 (functional) = 7.5 nM Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA ChEMBL. 18307290
EC50 (functional) = 7.5 nM Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA ChEMBL. 18307290
EC50 (functional) = 200 nM Agonist activity at human beta1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA ChEMBL. 18307290
EC50 (functional) = 200 nM Agonist activity at human beta1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA ChEMBL. 18307290
Ratio (binding) = 0.86 Intrinsic activity at human beta3 adrenergic receptor expressed in CHO cells assessed as ratio between maximal effect of drug to maximal effect of isoproterenol by EIA ChEMBL. 18307290
Ratio (ADMET) = 0.7 Ratio of Cmax for drug to Cmax for [4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-phenoxy)-phenoxy]-acetic acid in dog at 0.32 or 1.0 mg/kg, po by casette assay ChEMBL. 18307290
Ratio (binding) = 0.86 Intrinsic activity at human beta3 adrenergic receptor expressed in CHO cells assessed as ratio between maximal effect of drug to maximal effect of isoproterenol by EIA ChEMBL. 18307290
Ratio (ADMET) = 1.9 Ratio of AUC for drug to AUC for [4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-phenoxy)-phenoxy]-acetic acid in dog at 0.32 or 1.0 mg/kg, po by casette assay ChEMBL. 18307290
Ratio EC50 (binding) = 27 Ratio of EC50 for human beta3 adrenergic receptor over EC50 for human beta1 adrenergic receptor ChEMBL. 18307290

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.